Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

RecoverLINK Technology Pilot for HF Patients
Pilot to Assess Feasibility of Using RecoverLINK Technology to Supplement Outpatient Care for Heart Failure Patients
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
RecoverLINK Technology Pilot for HF Patients
Pilot to Assess Feasibility of Using RecoverLINK Technology to Supplement Outpatient Care for Heart Failure Patients
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
Barnes-Jewish Hospital-Washington University Hospital
mi
from
Saint Louis, MO
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
Barnes-Jewish Hospital-Washington University Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
University Hospital Cleveland Medical Center
mi
from
Cleveland, OH
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
University Hospital Cleveland Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated:  12/31/1969
University of Vermont
mi
from
Burlington, VT
Characterizing HIV-related Diastolic Dysfunction
Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network
Status: Enrolling
Updated: 12/31/1969
University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated:  12/31/1969
Phoenix Cardiovascular Research Group, LLC
mi
from
Phoenix, AZ
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated: 12/31/1969
Phoenix Cardiovascular Research Group, LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated:  12/31/1969
Baptist Heart Specialists Research
mi
from
Jacksonville, FL
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated: 12/31/1969
Baptist Heart Specialists Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated:  12/31/1969
South Miami Heart Specialists
mi
from
Miami, FL
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated: 12/31/1969
South Miami Heart Specialists
mi
from
Miami, FL
Click here to add this to my saved trials
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated:  12/31/1969
Cardiology Partners
mi
from
Wellington, FL
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated: 12/31/1969
Cardiology Partners
mi
from
Wellington, FL
Click here to add this to my saved trials
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated:  12/31/1969
The Lindner Research Center
mi
from
Cincinnati, OH
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated: 12/31/1969
The Lindner Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated:  12/31/1969
Florida Heart Center
mi
from
Fort Pierce, FL
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated: 12/31/1969
Florida Heart Center
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated:  12/31/1969
First Coast Cardiology
mi
from
Jacksonville, FL
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated: 12/31/1969
First Coast Cardiology
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated:  12/31/1969
BryanLGH Medical Center East
mi
from
Lincoln, NE
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated: 12/31/1969
BryanLGH Medical Center East
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated:  12/31/1969
St. Louis Heart and Vascular
mi
from
Saint Louis, MO
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated: 12/31/1969
St. Louis Heart and Vascular
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated:  12/31/1969
Universitätsklinikum St. Pölten
mi
from
St. Pölten,
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status: Enrolling
Updated: 12/31/1969
Universitätsklinikum St. Pölten
mi
from
St. Pölten,
Click here to add this to my saved trials
Insulin Resistance and Atherosclerosis in Women With Lupus
Insulin Resistance and Atherosclerosis in a Sample of Women With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Insulin Resistance and Atherosclerosis in Women With Lupus
Insulin Resistance and Atherosclerosis in a Sample of Women With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Splanchnic Nerve Anesthesia in Heart Failure
Splanchnic Nerve Block for Acute Heart Failure
Status: Enrolling
Updated:  12/31/1969
Duke
mi
from
Durham, NC
Splanchnic Nerve Anesthesia in Heart Failure
Splanchnic Nerve Block for Acute Heart Failure
Status: Enrolling
Updated: 12/31/1969
Duke
mi
from
Durham, NC
Click here to add this to my saved trials
Timing of VTE Prophylaxis in TBI
Timing of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury
Status: Enrolling
Updated:  12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Timing of VTE Prophylaxis in TBI
Timing of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury
Status: Enrolling
Updated: 12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Utility of Bowel Ultrasound in Diagnosing Necrotizing Eneterocolitis in Congenital Heart Disease
Pilot Randomized Control Trial of Necrotizing Enterocolitis Screening Using Abdominal Radiograph Versus Bowel Ultrasound Plus Abdominal Radiograph in Congenital Heart Disease Patients
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Utility of Bowel Ultrasound in Diagnosing Necrotizing Eneterocolitis in Congenital Heart Disease
Pilot Randomized Control Trial of Necrotizing Enterocolitis Screening Using Abdominal Radiograph Versus Bowel Ultrasound Plus Abdominal Radiograph in Congenital Heart Disease Patients
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated:  12/31/1969
Yale-New Haven Hospital
mi
from
New Haven, CT
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated: 12/31/1969
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated:  12/31/1969
Duke Health Center at Southpoint
mi
from
Durham, NC
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated: 12/31/1969
Duke Health Center at Southpoint
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania (Penn Heart and Vascular Center)
mi
from
Philadelphia, PA
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania (Penn Heart and Vascular Center)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Mechanistic Effects of Colchicine in Patients With Myocardial Infarction
Mechanistic Effects of Colchicine in Patients With Myocardial Infarction A Single Center Phase 4 Single Arm Open-label Study Evaluating the FDA-approved Drug, Colchicine, at the FDA-approved Gout Dose in Patients With Myocardial Infarction
Status: Enrolling
Updated:  12/31/1969
New York University School of Medicine
mi
from
New York, NY
Mechanistic Effects of Colchicine in Patients With Myocardial Infarction
Mechanistic Effects of Colchicine in Patients With Myocardial Infarction A Single Center Phase 4 Single Arm Open-label Study Evaluating the FDA-approved Drug, Colchicine, at the FDA-approved Gout Dose in Patients With Myocardial Infarction
Status: Enrolling
Updated: 12/31/1969
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
Thomas Hospital
mi
from
Fairhope, AL
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
Thomas Hospital
mi
from
Fairhope, AL
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
The Vascular Experts
mi
from
Stratford, CT
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
The Vascular Experts
mi
from
Stratford, CT
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
Christiana Hospital
mi
from
Newark, DE
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
South Florida Vascular Institute
mi
from
Coconut Creek, FL
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
South Florida Vascular Institute
mi
from
Coconut Creek, FL
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
North Florida Regional Medical Center
mi
from
Gainesville, FL
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
North Florida Regional Medical Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Medical Center
mi
from
Miami Beach, FL
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
Florida Hospital
mi
from
Orlando, FL
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Heartland Medical Center
mi
from
Sebring, FL
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Heartland Medical Center
mi
from
Sebring, FL
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
Kaiser Foundation Hospitals
mi
from
Honolulu, HI
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
Kaiser Foundation Hospitals
mi
from
Honolulu, HI
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
St. Joseph Hospital
mi
from
Fort Wayne, IN
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
St. Joseph Hospital
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
Community Hospital
mi
from
Munster, IN
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
Community Hospital
mi
from
Munster, IN
Click here to add this to my saved trials
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated:  12/31/1969
King's Daughters Medical Center- Kentucky Heart Institute
mi
from
Ashland, KY
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Status: Enrolling
Updated: 12/31/1969
King's Daughters Medical Center- Kentucky Heart Institute
mi
from
Ashland, KY
Click here to add this to my saved trials